Company profile

Structure Therapeutics Inc.

Pipeline7 assets

AleniglipronGSBR-1290 / GLP-1R / Oral small molecule agonist / Metabolic / Obesity
Obesity / overweight with weight-related comorbidityPhase 2 (ACCESS / ACCESS II); Phase 3 planned 2H 2026Active; End-of-Phase 2 FDA meeting Q2 2026GlobalType 2 diabetes mellitus with obesity/overweightPhase 2Enrolling (38-week study)Global
ACCG-2671ACCG-2671 / Amylin/calcitonin receptor (DACRA) / Oral small molecule agonist / Metabolic / Obesity
ObesityPhase 1Active (SAD study initiated Dec 2025)Global
ACCG-3535ACCG-3535 / Amylin/calcitonin receptor (DACRA) / Oral small molecule agonist / Metabolic / Obesity
ObesityPreclinical / IND-enablingPhase 1 initiation expected 2H 2026Global
ANPA-0073ANPA-0073 / Apelin (APJ) receptor / Oral small molecule biased agonist / Metabolic / Obesity
Obesity (selective/muscle-sparing weight loss)Phase 2 readyPhase 1 SAD/MAD completedGlobal
LTSE-2578LTSE-2578 / LPA1R (lysophosphatidic acid 1 receptor) / Oral small molecule antagonist / Pulmonary / Fibrosis
Idiopathic pulmonary fibrosis (IPF)Phase 1Phase 1 SAD/MAD completedGlobal
GIPR ProgramGIPR (and GLP-1R/GIPR) / Oral small molecule (agonist/antagonist) / Metabolic / Obesity
Obesity and related diseasesDiscovery / PreclinicalActiveGlobal
GCGR ProgramGCGR (and GLP-1R/GCGR) / Oral small molecule agonist / Metabolic / Obesity
Obesity and related diseasesDiscovery / PreclinicalActiveGlobal

Latest news7 items

Jun 5, 2026

Structure Therapeutics Announces Publication in Nature Medicine Highlighting Phase 2b ACCESS Program of Aleniglipron for Obesity

Publication presented concurrently with oral presentation at American Diabetes Association’s 86th Scientific Sessions from ACCESS development program with aleniglipron, a once-daily oral small molecule GLP-1 receptor agonist Publication and presentation detail dose-dependent, clinically meaningful

Presentation / Abstract • Phase 2ADA late-breaker poster session Sun, Jun 7, 2026, 12:30 PM CT

May 26, 2026

Structure Therapeutics Announces Participation in Upcoming Investor Conferences

SAN FRANCISCO, May 26, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced that management will participate in two

May 7, 2026

Structure Therapeutics Reports First Quarter 2026 Financial Results and Recent Highlights

Reported positive results from aleniglipron Phase 2 ACCESS II study with up to 16.3% body weight loss, demonstrating highest efficacy among oral GLP-1RAs at the 44-week time point and potentially comparable efficacy to injectable GLP1-RAs Data from ACCESS OLE expected in Q3 2026; Data from the

Trial Results • Phase 2

Apr 27, 2026

Structure Therapeutics to Present Aleniglipron, Amylin and Combination Data at the American Diabetes Association 86th Scientific Sessions

SAN FRANCISCO, April 27, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced multiple presentations at the American

Presentation / Abstract • Phase 2

Apr 14, 2026

Structure Therapeutics Appoints Matthew Lang, J.D. as Chief Operating Officer and General Counsel

SAN FRANCISCO, April 14, 2026 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today announced the appointment of Matthew Lang, J.D.

Mar 16, 2026

Structure Therapeutics Reports Positive Topline Data from Phase 2 ACCESS II Trial with Once-Daily Oral Small Molecule GLP-1 Receptor Agonist, Aleniglipron

Placebo-adjusted mean weight loss of 16.3% (39 lbs) at 180 mg and 16.0% (37 lbs) at 240 mg at 44 weeks with no evidence of weight loss plateau in ACCESS II, demonstrating highest efficacy among oral GLP-1RAs and comparable efficacy to injectable GLP1-RAs Continued weight loss up to 16.2% (40.5 lbs)

Trial Results • Phase 2

Feb 26, 2026

Structure Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Highlights

Positive results from the aleniglipron Phase 2 ACCESS programs in December 2025 demonstrated significant weight loss across all doses and up to 15.3% at 36 weeks Topline 44-week data from the ACCESS II study with higher doses expected in Q1 2026 Aleniglipron Phase 3 initiation expected in 2H 2026